(b) the antagonist antibody is a Fab, modified Fab, Fab', modified Fab', F(ab')$_2$, Fv, single domain antibody or an scFv.

64. The method according to claim **58**, wherein the antagonist is a polynucleotide encoding an anti-Gremlin-1 antibody comprising a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9, or an expression vector carrying said polynucleotide.

65. The method according to claim **58**, wherein the antagonist antibody is comprised in a pharmaceutical composition further comprising a pharmaceutically acceptable adjuvant and/or carrier.

66. The method according to claim **51**, wherein:

(a) the method comprises separate, sequential or simultaneous administration of an additional anti-cancer agent; optionally wherein said additional anti-cancer agent is a chemotherapeutic agent; and/or

(b) the method comprises separate, sequential or simultaneous radiotherapy. 67 (New). A composition or kit comprising an anti-GREM1 antagonist and an additional anti-cancer agent.

68. The composition or kit according to claim **67**, wherein:

(a) the anti-GREM1 antagonist is an anti-Gremlin-1 antibody comprising a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9;

(b) the additional anti-cancer agent is a chemotherapeutic agent; and/or

(c) (i) said anti-cancer or chemotherapeutic agent is suitable for treatment of colorectal cancer, optionally selected from 5-fluoruracil, oxaliplatin, irinotecan, folinic acid, cetuximab, nivolumab or bevacizumab; or

(ii) said anticancer or chemotherapeutic agent is suitable for treatment of multiple myeloma, optionally selected from an anti-CD38 antibody, an anti-SLAMF7 antibody, an anti-IL-6 antibody, or bortezumib or iMID (lenalidomide/pomalenomide) or an analogue of either thereof.

69. The composition or kit according to claim **68**, wherein the anti-CD38 antibody is daratumumab.

70. The composition or kit according to claim **68**, wherein the anti-SLAMF7 antibody is elotuzumab.

71. The composition or kit according to claim **68**, wherein the anti-IL-6 antibody is siltuximab.

72. A method for:

(a) detecting cancer in a patient, the method comprising measuring stromal expression of GREM1 in the patient, wherein stromal overexpression of GREM1 indicates that the patient comprises a cancer;

(b) prognosing a cancer in a patient, the method comprising determining whether or not the cancer comprises stromal overexpression of GREM1, wherein stromal overexpression of GREM1 in the cancer indicates that the patient has a worse prognosis than in the situation of normal stromal expression of GREM1;

(c) determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to treatment with a chemotherapeutic agent, which method comprises measuring stromal expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the chemotherapeutic agent; or

(d) determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to treatment with a GREM1 antagonist, the method comprising measuring stromal expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the GREM1 antagonist.

* * * * *